Cyberonics’ Sharpened Focus Buoys Stock 13% In May; OTC Index Off 2.6%
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics' revised NCP vagus nerve stimulation development plan for depression, combined with a sharper focus on epilepsy and fiscal fourth-quarter performance ahead of Wall Street expectations, led to a 12.5% stock gain in May
You may also be interested in...
Cyberonics Cuts Investment In VNS Depression Indication; Q4 Sales Up 64%
Cyberonics expects to scale-back its investment in developing a depression indication for its NeuroCybernetic Prosthesis vagus nerve stimulation system by 25% in fiscal 2003
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.